Sildenafil produces antinociception and increases morphine antinociception in the formalin test

European Journal of Pharmacology

Volumn 400, Issue 1, 2000, Pages 81-87

  Mixcoatl Zecuatl, Teresa ^a   Aguirre Bañuelos, Patricia ^a   Granados Soto, Vinicio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

cGMP; Morphine; N(G) L nitro arginine methyl ester (L NAME); Naloxone; ODQ (1H 1,2,4 oxadiazolo 4,3 a quinoxalin 1 one); Sildenafil

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; FORMALDEHYDE; MORPHINE; N(G) NITROARGININE METHYL ESTER; NALOXONE; OPIATE RECEPTOR; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HINDLIMB; HYDROLYSIS; HYPERALGESIA; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT;

ANALGESICS; ANIMALS; CYCLIC GMP; DRUG SYNERGISM; FEMALE; FORMALDEHYDE; GUANYLATE CYCLASE; MORPHINE; NALOXONE; NG-NITROARGININE METHYL ESTER; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, WISTAR;

EID: 0342657052     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00361-7     Document Type: Article

References (35)

1. Abbot F.V. Peripheral and central antinociceptive actions of ethylketocyclazocine in the formalin test. Eur. J. Pharmacol. 152:1988;93-100.
2. Aguirre-Bañuelos P., Castañeda-Hernández G., López-Muñoz F.J., Granados-Soto V. Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia. Eur. J. Pharmacol. 377:1999;175-182.
3. Aley K.O., McCarter G., Levine J.D. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J. Neurosci. 18:1998;7008-7014.
4. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-745.
5. Boolell M., Gepi-Attee S., Gingell C.J.G., Price M.E., Tang K., Turner L.A., Naylor A.M. Sildenafil, a novel effective treatment for male erectile dysfunction. Br. J. Urol. 78:1996;257-261.
6. Cunha F.Q., Texeira M.M., Ferreira S.H. Pharmacological modulation of secondary mediator systems - cyclic AMP and cyclic GMP - on inflammatory hyperalgesia. Br. J. Pharmacol. 127:1999;671-678.
7. Duarte I.D.G., Lorenzetti B.B., Ferreira S.H. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur. J. Pharmacol. 186:1990;289-293.
8. Duarte I.D.G., Santos I.R., Lorenzetti B.B., Ferreira S.H. Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur. J. Pharmacol. 217:1992;225-227.
9. Ferreira S.H., Nakamura M. Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins. 18:1979;191-200.
10. Ferreira S.H., Duarte I.D.G., Lorenzetti B.B. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur. J. Pharmacol. 201:1991;121-122.
11. Granados-Soto V., Flores-Murrieta F.J., Castañeda-Hernández G., López-Muñoz F.J. Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac in the rat. Eur. J. Pharmacol. 277:1995;281-284.
12. Granados-Soto V., Rufino M.O., Gomes Lopes L.D., Ferreira S.H. Evidence for the involvement of nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur. J. Pharmacol. 287:1997;281-284.
13. Haley J.E., Dickenson A.H., Schachter M. Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology. 31:1992;251-258.
14. Hong Y., Abbot F.V. Peripheral opioid modulation of pain and inflammation in the formalin test. Eur. J. Pharmacol. 277:1995;21-28.
15. Ethical guidelines for investigations on experimental pain in conscious animals. Pain. 16:1983;109-110.
16. Kawabata A., Manabe S., Manabe Y., Takagi H. Effect of topical administration of L-arginine on formalin-induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. Br. J. Pharmacol. 112:1994;547-550.
17. Levine J.D., Taiwo Y.O. Involvement of the mu-opiate receptor in peripheral analgesia. Neuroscience. 32:1989;571-575.
18. López-Muñoz F.J., Castañeda-Hernández G., Flores-Murrieta F.J., Granados-Soto V. Effect of caffeine coadministration and nitric oxide synthesis inhibition on the antinociceptive action of ketorolac. Eur. J. Pharmacol. 308:1996;275-277.
19. Lorenzetti B.B., Ferreira S.H. Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. Inflammation Res. 45:1996;308-311.
20. Malmberg A.B., Yaksh T.L. Antinociceptive actions of spinal non-steroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 263:1992;136-146.
21. Malmberg A.B., Yaksh T.L. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test. Pain. 54:1993;291-300.
22. Millan M.J. Multiple opioid systems and pain. Pain. 27:1986;303-347.
23. Moreland R.B., Goldstein I., Kim N.N., Traish A. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol. Metab. 10:1999;97-104.
24. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., Radomski M.W., Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1480-1485.
25. Nagasaka H., Awad H., Yaksh T.L. Peripheral and spinal actions of opioids in the blockade of the autonomic response evoked by compression of the inflamed knee joint. Anesthesiology. 85:1996;808-816.
26. 2-induced mechanical hyperalgesia in the rat. Neuroscience. 64:1995;769-776.
27. Pataki I., Telegdy G. Further evidence that nitric oxide modifies acute and chronic morphine actions in mice. Eur. J. Pharmacol. 357:1998;157-162.
28. Pyne N.J., Arshvsky V., Lochhead A. cGMP signal termination. Biochem. Soc. Trans. 24:1996;1019-1022.
29. Smith J.A.M., Amagasu S.M., Eglen R.M., Hunter J.C., Bley K.R. Characterization of prostanoid receptor-evoked responses in rat sensory neurons. Br. J. Pharmacol. 124:1998;513-523.
30. Stacey P., Rulten S., Dapling A., Phillips S.C. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Biophys. Res. Commun. 247:1998;249-254.
31. Stein C., Millan M.J., Shippenberg T.S., Peter K., Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther. 248:1989;1269-1275.
32. Stein C., Hassan A.H.S., Lehberger K., Giefing J., Yassouridis A. Local analgesic effect of endogenous opioid peptides. Lancet. 342:1993;321-324.
33. Taiwo Y.O., Levine J.D. Further confirmation of the role of adenylyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience. 44:1991;131-135.
34. Terrett N.K., Bell A.S., Brown D., Ellis P. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6:1996;1819-1824.
35. Tonussi C.R., Ferreira S.H. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur. J. Pharmacol. 251:1994;173-179.